TABLE 1.

Summary of Mouse Experiments

Treatment	Cells injected	Cures (n)
Group 1	1 × 106	0/5
Untreated
213Bi-rituximab, 925 kBq (day 7)	1 × 106	0/5
213Bi-rituximab, 3,700 kBq (day 7)	1 × 106	0/5
213Bi, free, 1,295 kBq (day 7)	1 × 106	0/5
213Bi-HER2/neu, 1,295 kBq (day 7)	1 × 106	0/5
10 μg of rituximab (day7)	1 × 106	0/5
Group 2	5 × 105	0/6
Untreated
213Bi-rituximab, 2,775 kBq (day 7)	5 × 105	2/6
213Bi-rituximab, 2,775 kBq (days 7, 13)	5 × 105	3/7
10 μg of rituximab (days 7, 13)	5 × 105	1/4
213Bi-HER2/neu, 2,775 kBq (day 7)	5 × 105	0/5
Group 3	1 × 106	0/6
Untreated
213Bi-rituximab, 2,775 kBq (day 7)	1 × 106	0/6
213Bi-rituximab, 2,775 kBq (days 7, 12)	1 × 106	0/6
213Bi-rituximab, 2,775 kBq (days 7, 12, 19)	1 × 106	0/6
Group 4	1 × 106	0/8
Untreated
213Bi-rituximab, 3,700 kBq (day 4)	1 × 106	6/8
131I-tositumomab, 2,035 kBq (day 4)	1 × 106	6/8
90Y-rituximab, 925 kBq (day 4)	1 × 106	0/8
10 μg of rituximab (day 4)	1 × 106	1/8